Zai Lab (MEX:ZLAB N) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ZLAB N Zai Lab Ltd MEX:ZLAB N
64 GF Score
Price MXN810.00
GF Value MXN1,177.76
! 7 Warning Signs
View Full Analysis

What is Zai Lab Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

MEX:ZLAB N
64GF Score
Zai Lab Ltd MEX:ZLAB N
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zai Lab (MEX:ZLAB N) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of MXN810.00 is trading 31.2% below its estimated GF Value™ of MXN1,177.76.

Key valuation signals for MEX:ZLAB N:

  • Dividend-Payout-to-FFO:
  • GF Value™: MXN1,177.76 vs. price of MXN810.00 (31.2% below fair value)
  • GF Score™: 64/100 with 7 warning signs

No single metric tells the full story. See the MEX:ZLAB N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zai Lab Business Description

Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score

Get the complete analysis for MEX:ZLAB N

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN810.00
Price
MXN1,177.76
GF Value